相关实验视频
Updated: Jul 8, 2025

08:39
A Murine Model of Hemodialysis Access-Related Hand Dysfunction
Published on: May 31, 2022
1.7K
在接受不同抗凝固剂的血液透析患者中,有异常的肉丁代谢
Kie Sekiguchi1, Takaya Abe1, Ei Shiomi1
1Department of Urology, School of Medicine, Iwate Medical University, Morioka, Iwate, Japan.
概括
在血液透析患者中,低分子量肝素 (LH) 与未分离肝素 (UH) 相比,对卡尼丁代谢的影响较小. 这表明LH可能更适合患有脂质代谢改变的患者.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 氨酸的使用在血液透析中很常见.
- 异常的卡尼丁代谢是慢性病患者的关注点.
研究的目的:
- 为了研究未分离的氨酸 (UH) 和低分子量氨酸 (LH) 对血液透析患者的卡尼丁代谢的差异影响.
主要方法:
- 在血液透析前后评估血清自由脂肪酸 (FFAs) 和乙卡尼丁与自由卡尼丁比率 (AC/FC) 的变化.
- 在接受UH和LH的患者之间比较了这些参数.
- 检查了从LH切换到UH的影响.
主要成果:
- 与LH组相比,UH组的AC/FC比率明显高于LH组.
- 在UH组中,血清FFA在透析后显著增加,与AC/FC正相关.
- 从LH转换为UH的患者在3个月后显示了AC/FC的显著增加.
结论:
- 在血液透析患者中,未分离的氨酸 (UH) 比低分子量氨酸 (LH) 显著影响卡尼丁和脂质代谢.
- 似乎LH对脂质和卡尼丁代谢具有较轻的作用,可能为某些患者群体提供更安全的替代方案.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
708
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
708
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Dialysis
321
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
321
Disorders of Hemostasis
922
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
922
Renal Failure: Dose Adjustments
95
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
95
Factors Affecting Protein-Drug Binding: Patient-Related Factors
61
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
61

